Opendata, web and dolomites

denovoSkin

Personalized, bio-engineered skin grafts for the permanent treatment of skin defects.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 denovoSkin project word cloud

Explore the words cloud of the denovoSkin project. It provides you a very rough idea of what is the project "denovoSkin" about.

minimally    site    therapy    health    sound    painful    issue    scar    bio    dermo    care    off    burns    denovoskin    investment    stamp    surgical    treatment    function    psychosocial    corrective    restore    life    plan    meet    suffer    starting    autografting    sized    impair    performance    global    hence    follow    savings    transplantation    reduce    rehabilitation    disfiguring    financial    manufacture    atmp    orphan    economic    chain    16    engineered    drug    solid    considerable    interventions    personalized    demand    leaves    considerably    ema    intense    projected    human    medical    avoids    every    donor    instrument    epidermal    scars    biopsy    intervention    skin    patients    world    granted    market    quantities    debilitating    solving    deployment    permanent    patented    invested    wounds    quality    swissmedic    standard    structure    classified    57m    trade    homecare    50m    designation    last    fast    automation    excision    shortage    graft    significantly    burden    surgeries    fits    defects    sme    commercialisation    movement    fda    clinical    outstanding    patient    14m   

Project "denovoSkin" data sheet

The following table provides information about the project.

Coordinator
CUTISS AG 

Organization address
address: WEINBERGSTRASSE 35 WYSS TRANSLATIONAL CENTER ZURICH DENOVOS
city: ZURICH
postcode: 8006
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://cutiss.swiss/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CUTISS AG CH (ZURICH) coordinator 50˙000.00

Map

 Project objective

Every year in the world, more than 50M patients suffer from skin defects (e.g. burns, excision, etc.) and need surgical intervention to restore skin function. Standard of care, skin autografting, very often leaves these patients with scars. Scars are permanent and disfiguring, and can also be painful and highly debilitating. Indeed, they may also impair movement and growth, and require several follow-up surgeries, intense homecare and psychosocial rehabilitation. Hence, scars significantly affect patient’s quality of life, along with the economic burden for the health-care system. Furthermore, in the case of large wounds, donor site shortage represents a real clinical issue. denovoSkin™ is a patented, personalized, bio-engineered human skin graft classified as Advanced Therapy Medical Product (ATMP). It is engineered in large quantities starting-off from a stamp-sized skin biopsy of the patient, thus solving the donor site shortage issue. Moreover, because of its dermo-epidermal structure, denovoSkin is expected to minimally scar after transplantation. Its outstanding performance could considerably reduce or even avoids further corrective interventions, allowing for considerable savings in terms of costs. denovoSkin™ is granted with Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA. So far, more than €14M have been invested over the last 16 years of research into the development and the clinical testing of denovoSkin™. To have denovoSkin™ fully projected at a European and global level we need a further investment of €3.57M to set up a solid EU value chain able to meet the large demand expected during the commercialisation via developing the automation of manufacture. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of denovoSkin™ and its market uptake.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DENOVOSKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DENOVOSKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

SUPPLEPRINT (2018)

Super Productive Line Printing Inkjet

Read More  

Volumizer (2018)

A natural, non-surgical, and safe facial filler which treats the root cause of facial ageing.

Read More  

STAR (2018)

Safe, Transparent, Active and Reliable mineral sunscreen technology

Read More